

# Bird & Bird International Capital Markets Annual review 2021

We advised **Experience Co Limited**, an ASX-listed adrenalin sports and leisure company on key aspects of its diversification program in light of the new Covid environment, including the acquisition of the assets of Maria Island Walk (one of the 'Great Walks of Australia' located in Tasmania) and Wild Bush Luxury (with assets located in the Flinders Ranges in South Australia and Kakadu in the Northern Territory).

AUSTRALIAN SECURITIES EXCHANGE

We advised **BOLD's** (Business Opportunities for L'Oréal Development) investment as shareholder as part of Global Bioenergies's capital increase on Euronext Growth for a total amount of EUR14.5 million.

EURONEXT GROWTH

We advised Nominated Adviser and Broker, **Liberum Capital Limited** in connection with the placing of 7,138,998 ordinary shares in AIM-listed Conygar Investment Company PLC, a placing which raised GBP10.7 million. The Conygar Investment Company PLC is a property investment and development company dealing primarily in the UK.

AIM MARKET, LONDON STOCK EXCHANGE

We advised **9 Spokes Limited**, a New Zealand headquartered ASX listed company, on the management of an unsolicited potential takeover bid or scheme of arrangement to acquire all the shares in the company, and the subsequent termination of that proposed transaction.

AUSTRALIAN SECURITIES EXCHANGE

We advised the Nominated Adviser, **Strand Hanson Limited**, and the brokers, H&P Advisors Limited and VSA Capital Group Limited, on Tungsten West's IPO and admission to the AIM market. Tungsten West is the 100% owner and operator of the Hemerdon tungsten and tin mine in South Devon, UK, and is one of the largest tungsten resources in the world.

AIM MARKET, LONDON STOCK EXCHANGE

We advised **Toivo Group Plc** in connection with its oversubscribed EUR 15 million initial public offering and listing on Nasdaq First North Growth Market Finland.

NASDAQ FIRST NORTH GROWTH MARKET  
FINLAND

We advised Nominated & Financial Adviser **Strand Hanson Limited** on the admission of Future Metals NL to AIM. Future Metals is a platinum group metals exploration and development company that holds a 100% interest in the Panton Project in Western Australia.

AIM MARKET, LONDON STOCK EXCHANGE

We advised **Administer Plc** in connection with its oversubscribed EUR14 million IPO and listing on Nasdaq First North Growth Market Finland.

NASDAQ FIRST NORTH GROWTH MARKET  
FINLAND

Advised **Sensetime Group Inc.**, an artificial intelligence company, on matters of Singapore laws in its initial public offering on the Hong Kong Stock Exchange that raised more than USD700 million.

HONG KONG STOCK EXCHANGE

We advised **Tekcapital plc**, a company that acquires and invests in breakthrough technologies that can improve quality of life, in a placing that raised GBP3 million for further investment in their portfolio innovation companies.

AIM MARKET, LONDON STOCK EXCHANGE

We advised **DP Poland**, the franchiser holder of Domino's Pizza in Poland, in a placing and subscription which raised GBP3 million to aid the expansion of Domino's in Poland.

AIM MARKET, LONDON STOCK EXCHANGE

We advised Haitong International Financial Products (Singapore) Pte. Ltd. on its subscription for HKD200 million in principal amount of secured and guaranteed structured notes.

HONG KONG STOCK EXCHANGE

We advised **Athesia** in the process of selling its interests in Retelit S.p.A. (an Italian company listed on the main market) in the context of the takeover by Marbles S.r.l.

BORSA ITALIANA

We advised **Asiamet Resources**, an AIM-listed copper mining client, on its GBP10m fundraising through a firm placing, subscription, and accelerated bookbuild.

AIM MARKET, LONDON STOCK EXCHANGE

Advised security and surveillance solutions provider **SECITS Holding** on its MSEK25 directed issue on Nasdaq First North Growth Market.

NASDAQ FIRST NORTH GROWTH MARKET

We advised **Cloudbreak Discovery PLC** on the acquisition of certain businesses and assets in Canada, which constituted a reverse takeover pursuant to rule 58 of the AQSE rules and the re-listing of the enlarged group to the Standard List of the London Stock Exchange's Main Market, together with an associated fundraise.

MAIN MARKET, LONDON STOCK EXCHANGE

We advised **Kreos Capital VI (Expert Fund) LP**, a market-leading growth debt investor in the technology and healthcare sectors, on a joint EUR10 million secured convertible loan with Pontifax Medison Finance Limited to Oxurion, a listed Euronext Brussels biopharmaceutical company developing innovative ophthalmic treatments.

EURONEXT BRUSSELS

We advised **Commerzbank, ING, and UniCredit** on their put and call option transaction with **MOL Plc**. MOL Plc is a Hungarian multinational oil and gas company.

BUDAPEST STOCK EXCHANGE

Acted for **LS 2 Holdings Limited**, as solicitors to the placement and legal advisers on Singapore law, in its initial public offering by way of placement on the Catalist Board of the Singapore Exchange.

CATALIST BOARD, SINGAPORE EXCHANGE

We advised **Leeds United Football Club Limited** on the admission to listing and trading of GBP22,450,000 Variable Funding Fixed Rate Notes due 2026 on The International Stock Exchange (Channel Islands).

THE INTERNATIONAL STOCK EXCHANGE

We advised investment holding company **Gazelle Capital** (as vendor) in relation to SGX Mainboard-listed Fabchem China Limited's proposed acquisition of Australian power plant operator Renewable Power Management for an approximate deal consideration of S\$22 million to S\$30 million.

SINGAPORE STOCK EXCHANGE

We advised **Checkin.com Group AB**, a Stockholm-based provider of cloud-based software for improved online check-in solutions, on its SEK45,000,000 IPO.

NASDAQ FIRST NORTH GROWTH MARKET

We advised **Joh. Berenberg Gossler & Co KG**, London branch and **Grant Thornton UK LLP** on the successful initial public offering of Supreme plc, a licenced manufacturer and supplier of consumer goods. This was the first AIM IPO of 2021; the placing was raised GBP67.5 million with a market cap of GBP156 million on Admission.

AIM MARKET, LONDON STOCK EXCHANGE

We advised **Serum Life Science Ltd**, the UK subsidiary of Serum Institute of India on their strategic investment at the value of just over GBP50 million into Oxford Biomedica plc.

MAIN MARKET, LONDON STOCK EXCHANGE,  
FTSE 250 INDEX

Acting as Singapore counsel to **Jobstore Group**, an online job distribution platform, in relation to its proposed listing on the Australian Securities Exchange.

AUSTRALIAN SECURITIES EXCHANGE

We advised Greentech company **Afyren** on its IPO on Euronext Growth Paris. The IPO consists of a primary offering of approximately EUR66.5 million, which may be increased to EUR72.8 million if the over-allotment option is exercised in full. The transaction is the first French Tech120 IPO outside of the Next40.

EURONEXT GROWTH PARIS

We advised **Envipco Holding N.V.**, a recognised leader in the development and operation of reverse vending machines listed on Euronext Amsterdam, on its EUR8.1m private placement, and its secondary listing on Euronext Growth Oslo.

EURONEXT AMSTERDAM, EURONEXT  
GROWTH OSLO

We advised **EnQuest PLC**, a UK independent oil and gas producer operating in the North Sea and Malaysia, on Swedish law aspects to its GBP36,100,000 placing and open offer.

MAIN MARKET, LONDON STOCK EXCHANGE,  
AND NASDAQ STOCKHOLM

Acted for **United Overseas Bank Limited**, as solicitors to the sponsor and issue manager and placement agent on Singapore law, in the initial public offering of Alpina Holdings Limited by way of placement on the Catalist Board of the Singapore Exchange.

CATALIST BOARD, SINGAPORE EXCHANGE

Advised **Sensetime Group Inc.**, an artificial intelligence company, on matters of Singapore laws in its initial public offering on the Hong Kong Stock Exchange that raised more than USD700 million.

HONG KONG STOCK EXCHANGE

We advised **Aedge Group Limited** on its initial public offering on the Catalist board of the SGX-ST.

SINGAPORE STOCK EXCHANGE

We advised **iX Biopharma Ltd**, a Singapore public-listed specialty pharmaceutical company focussing on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions, on its rights issue which raised net proceeds of USD9.56 million.

CATALIST BOARD, SINGAPORE EXCHANGE